ASCO 25

Oncology

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Digital

In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

Oncology

Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.

Oncology

Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.

Oncology

ASCO 2025 may be over, but the insights for the future of oncology are only just beginning.